FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read Date: February 12, 2025FDA Approves Adcetris OverviewThe FDA has approved a new combination therapy for adults with relapsed or refractory…
FDA Approves Mirdametinib: Is this the Breakthrough NF1-PN Patients Have Been Waiting For? Other 3 Mins Read FDA Approves Mirdametinib for NF1-PN: A New Option for PatientsIntroduction: The FDA has recently approved Mirdametinib (Gomekli) from SpringWorks Therapeutics…
